Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges
European Journal of Cancer2017Vol. 78, pp. 16–23
Citations Over TimeTop 10% of 2017 papers
Etienne Giroux‐Leprieur, Coraline Duménil, Catherine Julié, Violaine Giraud, Jennifer Dumoulin, Sylvie Labrune, Thierry Chinet
Related Papers
- → A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes(2016)117 cited
- → Advances in the Treatment of Non–small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab(2016)38 cited
- → Immunotherapy protocols in lung cancer(2018)9 cited
- → Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer(2022)8 cited
- → Porównanie pośrednie wyników leczenia chorych na zaawansowane/przerzutowe czerniaki za pomocą niwolumabu lub pembrolizumabu – analiza wieloośrodkowa(2020)1 cited